Rosalin Mishra

5PUBLICATIONS
5CO-AUTHORS
Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 23, 2022
HER3 Alterations in Cancer and Potential Clinical Implications.

Mary Kate Kilroy, SoYoung Park, Wasim Feroz

|Nov 27, 2021
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.

Hima Patel, Rosalin Mishra, Nour Yacoub

|Apr 03, 2021
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

Rosalin Mishra, Hima Patel, Samar Alanazi

|Mar 06, 2021
Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth.

Rosalin Mishra, Long Yuan, Hima Patel

|Jun 27, 2020
BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels.

Long Yuan, Rosalin Mishra, Hima Patel

Pageof 1

Frequent Collaborators

3 joint publications

Samar Alanazi

1 joint publications

Aniruddha S Karve

1 joint publications

Aaron White

1 joint publications

Mary Kate Kilroy